Division of Anesthesia, Intensive Care, and Pain Management, Tel-Aviv Medical Center, Tel-Aviv University, Tel-Aviv, Israel.
Division of Anesthesia, Intensive Care, and Pain Management, Tel-Aviv Medical Center, Tel-Aviv University, Tel-Aviv, Israel; Outcomes Research Consortium, Cleveland, OH, United States of America.
J Clin Anesth. 2024 Feb;92:111113. doi: 10.1016/j.jclinane.2023.111113. Epub 2023 Jun 4.
To evaluate the association between midazolam premedication and postoperative delirium in a large retrospective cohort of patients ≥70 years.
Retrospective cohort study.
A single tertiary academic medical center.
Patients ≥70 years having elective non-cardiac surgery under general anesthesia from 2020 to 2021.
Midazolam premedication, defined as intravenous midazolam administration prior to induction of general anesthesia.
The primary outcome, postoperative delirium, was a collapsed composite outcome including at least one of the following: a positive 4A's test during post-anesthesia care unit stay and/or the initial 2 postoperative days; physician or nursing records reporting new-onset confusion as captured by the CHART-DEL instrument; or a positive 3D-CAM test. The association between midazolam premedication and postoperative delirium was assessed using multivariable logistic regression, adjusting for potential confounding variables. As secondary analysis, we investigated the association between midazolam premedication and a composite of other postoperative complications. Several sensitivity analyses were performed using similar regression models.
In total, 1973 patients were analyzed (median age 75 years, 47% women, 50% ASA score ≥ 3, 32% high risk surgery). The overall incidence of postoperative delirium was 15.3% (302/1973). Midazolam premedication was administered to 782 (40%) patients (median [IQR] dose 2 [1,2] mg). After adjustment for potential confounding variables, midazolam premedication was not associated with increased odds of postoperative delirium, with adjusted odds ratio of 1.09 (95% confidence interval 0.82-1.45; P = 0.538). Midazolam premedication was also not associated with the composite of other postoperative complications. Furthermore, no association was found between midazolam premedication and postoperative delirium in any of the sensitivity analyses preformed.
Our results suggest that low doses of midazolam can be safely used to pre-medicate elective surgical patients 70 years or older before non-cardiac surgery, without significant effect on the risk of developing postoperative delirium.
评估在一个大型回顾性 70 岁以上患者队列中咪达唑仑预给药与术后谵妄之间的关联。
回顾性队列研究。
单一的三级学术医疗中心。
2020 年至 2021 年期间在全身麻醉下接受择期非心脏手术的 70 岁以上患者。
咪达唑仑预给药,定义为全身麻醉诱导前给予静脉咪达唑仑。
主要结局为术后谵妄,是一个综合指标,包括以下至少一项:麻醉后护理单元期间和/或最初 2 个术后天进行的 4A's 测试阳性;医生或护理记录报告新出现的意识混乱,如 CHART-DEL 仪器记录;或 3D-CAM 测试阳性。使用多变量逻辑回归评估咪达唑仑预给药与术后谵妄之间的关联,并调整潜在混杂变量。作为二次分析,我们研究了咪达唑仑预给药与其他术后并发症综合指标之间的关联。使用类似的回归模型进行了几次敏感性分析。
共分析了 1973 名患者(中位年龄 75 岁,47%为女性,50%ASA 评分≥3,32%为高风险手术)。术后谵妄总发生率为 15.3%(302/1973)。782 名(40%)患者给予咪达唑仑预给药(中位数[IQR]剂量 2 [1,2]mg)。在调整潜在混杂变量后,咪达唑仑预给药与术后谵妄的发生几率增加无关,调整后的比值比为 1.09(95%置信区间 0.82-1.45;P=0.538)。咪达唑仑预给药也与其他术后并发症综合指标无关。此外,在进行的任何敏感性分析中,均未发现咪达唑仑预给药与术后谵妄之间存在关联。
我们的研究结果表明,在 70 岁或以上的择期非心脏手术患者中,在非心脏手术前给予低剂量咪达唑仑镇静,可以安全地用于预给药,而不会显著增加术后谵妄的风险。